The medical and psychological sciences in general target serotonin through an pharmaceutical product called Serotonin. Re-uptake Inhibitors or an SSRI. Serotonin is key neurotransmitter. What is a neurotransmitter you ask? I would describe it as a chemical substance that is released at the end of a nerve fibre, assisting the transfer of the impulse to another nerve fibre. In short a neurotransmitter carries the message from one nerve cell to the next target cell, muscle cell or gland. It is important to understand this information, as well as understand that the 4 key neurotransmitters involved in mental health symptoms are; acetylcholine, serotonin, dopamine and GABA. An SSRI is only targeting serotonin.
The studies surrounding depression indicate that 89% of depressed patients are not benefiting from antidepressants. There is also controversy as to if targeting serotonin for mental health, as most pharmaceuticals do, is the right approach. Further, several studies have indicated that most people recover within about 12 to 13 weeks from depression and 85% recover within the year.
There are biotypes that we need to explore per individual. This exploration is to determine if an individual is in need of some supplemental depression support. The 4 bio types to explore are: 1) undermethylation, 2) folate deficiency, 3) copper overload, 4) pyrrole disorder which all can affect the neurotransmitter activity reducing serotonin and dopamine. As well there is a need to consider bio individual situations such as an elevated serotonin, dopamine, elevated norepinephrine. Also, what about reduced serotonin or GABA? All of these conditions could play a role in imbalances that can lead to symptoms of depression. Whew, so the point is serotonin is one but there are other options.
Have any questions, just ask me at info@mindhealthconnect.ca.